Literature DB >> 18683043

Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma.

Gloria Peiró1, Susana Benlloch, Laura Sánchez-Tejada, Encarna Adrover, Enrique Lerma, Francisca M Peiró, José Sánchez-Payá, F Ignacio Aranda.   

Abstract

Background The predictive value of IGF1R on local recurrence in invasive breast carcinoma (BC) is not well known. Methods In a series of 197 lymph-node negative BC patients treated with breast-conserving surgery and radiation therapy, we performed immunohistochemistry for alpha-IGF1R, beta-IGF1R (phosphorylated/active form) and Estrogen/Progesterone receptors. We further evaluated the IGF1R mRNA expression by quantitative RT-PCR and IGF1R mutations by direct DNA sequencing (exons 19 and 21) in 85 primary BC (42 control cases, 31 with local recurrence and 12 with distant metastasis) and in 31 local recurrences. Unconditional logistic regression analyses were performed to identify risk factors for recurrence. Results Local recurrences were associated with high-grade tumors, PR-negative and low active-IGF1R, which emerged as independent breast relapse predictors by multivariate analysis. Conclusion Patients with early BC treated with lumpectomy and radiation who have low-grade tumors and favorable markers (increased content of active IGF1R and PR-positive) have a low risk of local recurrence. Therefore, do not benefit from a boost dose on the surgical scar.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18683043     DOI: 10.1007/s10549-008-0139-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  7 in total

1.  Role of IGF-1 receptor in radiation response.

Authors:  Almudena Valenciano; Luis Alberto Henríquez-Hernández; Mercedes Moreno; Marta Lloret; Pedro Carlos Lara
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

Review 2.  Regulation of breast cancer metastasis by IGF signaling.

Authors:  Deepali Sachdev
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-22       Impact factor: 2.673

3.  Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.

Authors:  A Gallardo; E Lerma; D Escuin; A Tibau; J Muñoz; B Ojeda; A Barnadas; E Adrover; L Sánchez-Tejada; D Giner; F Ortiz-Martínez; G Peiró
Journal:  Br J Cancer       Date:  2012-03-27       Impact factor: 7.640

Review 4.  The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression.

Authors:  Arthur Adams; Aram S A van Brussel; Jeroen F Vermeulen; Willem P Th M Mali; Elsken van der Wall; Paul J van Diest; Sjoerd G Elias
Journal:  BMC Cancer       Date:  2013-11-10       Impact factor: 4.430

5.  Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.

Authors:  Sofie Björner; Ann H Rosendahl; Maria Simonsson; Andrea Markkula; Karin Jirström; Signe Borgquist; Carsten Rose; Christian Ingvar; Helena Jernström
Journal:  Oncotarget       Date:  2017-02-07

6.  The impact of the IGF-1 system of cancer cells on radiation response - An in vitro study.

Authors:  Senthiladipan Venkatachalam; Esther Mettler; Christian Fottner; Matthias Miederer; Bernd Kaina; Matthias M Weber
Journal:  Clin Transl Radiat Oncol       Date:  2017-10-05

7.  PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.

Authors:  Karin Beelen; Mark Opdam; Tesa M Severson; Rutger H T Koornstra; Andrew D Vincent; Jelle Wesseling; Jettie J Muris; Els M J J Berns; Jan B Vermorken; Paul J van Diest; Sabine C Linn
Journal:  Breast Cancer Res       Date:  2014-01-27       Impact factor: 6.466

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.